Abraxane (nab-paclitaxel) proved markedly more effective than conventional paclitaxel as part of a neoadjuvant regimen for patients with high-risk, early breast cancer, according to results presented ...

– Data from Pre-Clinical Studies to Be Presented at 101 st Annual Meeting of the American Association for Cancer Research – “This model was developed to increase our understanding of hard to treat ...

Pancreatic cancer is an aggressive, hard-to-treat disease, especially once it spreads outside the pancreas. Unfortunately, about 80 percent of pancreatic tumors are diagnosed at stage 4. Because of ...

Pomalyst and Abraxane are the next largest revenue generators for Celgene (CELG) after Revlimid. In the United States, Pomalyst is used to treat multiple myeloma patients who have gone through at ...

Abraxane plus gemcitabine was superior to gemcitabine alone with statistically significant and clinically meaningful results across primary and key secondary endpoints and patient subgroups Oral ...

Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for ...

LOS ANGELES--(BUSINESS WIRE)-- Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, previously announced it will be presenting more than 30 studies, including new clinical ...

Shortly after the Food and Drug Administration approved a combination using it with the first-ever immunotherapy drug to win the agency’s nod for breast cancer, a Celgene chemotherapy agent has failed ...

Dr. Patrick Soon-Shiong must be feeling nostalgic for the cancer blockbuster that launched his fortune: He’s circling back to his Abraxane roots with an interesting new Phase 3 buy. The pharmaceutical ...

In 3Q15, Celgene’s (CELG) oncology drug Abraxane managed to earn revenues of about $229.9 million, an 8.3% rise from the $212.2 million earned in 3Q14. Based on the drug’s performance, Celgene has ...

Abraxane, a cancer chemotherapy made by Celgene, slowed tumor growth and cut the risk of death in patients with advanced pancreatic cancer, according to results that will be presented at a conference ...